No significant difference in CD49b expression and cell member was observed between HD‐BMMSC and de novo AML‐BMMSC (738.50 [496.0‐981.0] vs 1246.0 [703.0‐1624.0] and 12.20% [8.90%‐15.50%] vs 47.45% [5.40%‐97.40%]), respectively, for HD‐BMMSC and de novo AML‐BMMSC (Figure 4A‐C). The gene discussed is ITGA2; the disease is acute myeloid leukemia.